The Abu Dhabi Stem Cell Centre (ADSCC) has entered into partnership with CellSave Arabia, the first private stem cell laboratory in the GCC region dedicated to storing stem cells from umbilical cord blood and tissue after birth. Harvested stem cells from the umbilical cord are currently being used to treat over 80 diseases and have tremendous potential for being used for life saving treatments in the future.

The ADSCC is a specialist healthcare centre that focusing on cell therapy to treat a variety of diseases and disorders, regenerative medicine, and researching future stem cell therapies. ADSCC has treated over 2000 patients suffering from COVID-19, with 1200 already fully recovered from the effects of the virus.

Dr Yendry Ventura, ADSCC, said “We are looking forward to working with CellSave Arabia and are very pleased to be able to enter this partnership and collaborate on future stem cell initiatives. Stem cell therapy is one of the fastest growing fields in medicine, and the potential for stem cell use in the future is vast.”

Mai Ibrahim, Chief Executive Officer at CellSave Arabia, said “We are very excited about working with Abu Dhabi Stem Cell Centre. The collaboration between CellSave Arabia and ADSCC will help spread awareness about stem cell banking and with the possibility of curing future diseases using stem cells.”

                                                

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.